The Innovative Medicines Initiative's New Drugs for Bad Bugs programme: European public–private partnerships for the development of new strategies to tackle antibiotic resistance
Tomislav Kostyanev(Institute for Health Metrics and Evaluation), Herman Goossens(Kaneka (United States)), Stacie Ross(GlaxoSmithKline (United Kingdom)), Gerhild Angyalosi(Novartis (Switzerland)), Anders Karlén(Uppsala University), R. deWinter(University Medical Center Utrecht), Stephan Harbarth(University Hospital of Geneva), Evelina Tacconelli(University of Verona), J.S. Elborn(Royal Brompton Hospital), Marc J. M. Bonten(Utrecht University), Alasdair MacGowan(Southmead Hospital), Hasan S. Jafri(AstraZeneca (Australia)), Cuong Vuong(AiCuris (Germany)), Mathias Winterhalter(Universität Hamburg), Bruno François(Inserm), Judith Hackett(AstraZeneca (United States)), Anne Witschi(Basilea Pharmaceutica (Switzerland)), Robert A. Stavenger(Howard Hughes Medical Institute), H. M. Steel(GlaxoSmithKline (United Kingdom)), Seamus O’Brien(Global Antibiotic Research & Development Partnership)
Cited by 129
Related Papers
Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal
|BMJ|2020|3.2k
Global increase and geographic convergence in antibiotic consumption between 2000 and 2015
|Proceedings of the National Academy of Sciences|2018|3.2k
A minimal common outcome measure set for COVID-19 clinical research
|The Lancet Infectious Diseases|2020|1.8k
Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del<i>CFTR</i>
|New England Journal of Medicine|2015|1.6k
Assessment of the worldwide burden of critical illness: the Intensive Care Over Nations (ICON) audit
|The Lancet Respiratory Medicine|2014|1.3k